Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection | Zendy

Nader Yatim | Zendy; Jérémy Boussier | Zendy; Pauline Tétu | Zendy; Nikaïa Smith | Zendy; Timothée Bruel | Zendy; Bruno Charbit | Zendy; Laura Barnabei | Zendy; Aurélien Corneau | Zendy; Laetitia Da Meda | Zendy; Clara Allayous | Zendy; Barouyr Baroudjian | Zendy; Majdi Jebali | Zendy; F. Herms | Zendy; Ludivine Grzelak | Zendy; Isabelle Staropoli | Zendy; Vincent Calmettes | Zendy; Jérôme Hadjadj | Zendy; Olivier Peyrony | Zendy; C. Cassius | Zendy; Jérôme LeGoff | Zendy; N. Kramkimel | Zendy; S. Aractingi | Zendy; Magnus Fontes | Zendy; Catherine Blanc | Zendy; Frédéric RieuxLaucat | Zendy; Olivier Schwartz | Zendy; Benjamin Terrier | Zendy; Darragh Duffy | Zendy; Célèste Lebbé | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection

Author(s) -

Nader Yatim,

Jérémy Boussier,

Pauline Tétu,

Nikaïa Smith,

Timothée Bruel,

Bruno Charbit,

Laura Barnabei,

Aurélien Corneau,

Laetitia Da Meda,

Clara Allayous,

Barouyr Baroudjian,

Majdi Jebali,

F. Herms,

Ludivine Grzelak,

Isabelle Staropoli,

Vincent Calmettes,

Jérôme Hadjadj,

Olivier Peyrony,

C. Cassius,

Jérôme LeGoff,

N. Kramkimel,

S. Aractingi,

Magnus Fontes,

Catherine Blanc,

Frédéric RieuxLaucat,

Olivier Schwartz,

Benjamin Terrier,

Darragh Duffy,

Célèste Lebbé

Publication year - 2021

Publication title -

science advances

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 5.928

H-Index - 146

ISSN - 2375-2548

DOI - 10.1126/sciadv.abg4081

Subject(s) - immunity , immune system , immunology , acquired immune system , inflammation , immune checkpoint , covid-19 , medicine , virology , biology , immunotherapy , disease , infectious disease (medical specialty) , pathology

The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 and investigated their transcriptomic, proteomic, and cellular profiles. We found that ICI treatment was not associated with severe COVID-19 and did not alter the induction of inflammatory and type I interferon responses. In-depth phenotyping demonstrated expansion of CD8 effector memory T cells, enhanced T cell activation, and impaired plasmablast induction in ICI-treated COVID-19 patients. The evaluation of specific adaptive immunity in convalescent patients showed higher spike (S), nucleoprotein (N), and membrane (M) antigen-specific T cell responses and similar induction of spike-specific antibody responses. Our findings provide evidence that ICI during COVID-19 enhanced T cell immunity without exacerbating inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research